 |
|
|||||
 |
 |
 |
 |
 |
|
 |
 |
 |
 |
 |
|
Team
Dr. Karsten Henco, Managing Partner
Dr Karsten Henco, Chairman of the Board of HS LifeSciences AG, started his industrial career in the 1980s when he was involved in the establishment of the molecular biology and recombinant DNA technology facilities of BASF AG in Ludwigshafen, Germany. In 1985 he was co-founder of Qiagen GmbH (now Qiagen NV) and served as the company's Managing Partner until 1993 when he became Managing Director and CEO of newly founded Evotec AG. He left Evotec in 2001 and, among others, served as CEO of U3 Pharma AG until 2007.
Dr. Henco studied biochemistry at the University of Hanover, Hanover Medical School, and Technische Hochschule Darmstadt (Germany). After receiving his doctorate in 1979, he was a post-doctoral fellow in the laboratory of Professor Charles Weissmann, the University of Zurich, where he cloned and characterized interferons and other important lymphokines.
Dr, Henco is Member or Chairman of several Supervisory Boards including Max Planck Innovation GmbH, IBMT Fraunhofer Institut, HS LifeSciences and QureInvest AG. He serves as a Vorstand at Deutsche Industrievereinigung Biotechnologie of VCI (German Chemical Industry Association) and acts as an advisor for HighTech Gründerfonds of the German government.
He is co-founder or co-founding investor of fourteen biotech companies in Germany, USA, Canada and Austria, such as Qiagen NV, Evotec AG, NewLab AG, Coley Pharmaceuticals Inc, U3 Pharma AG, Neurimmune Therapeutics AG, HS LifeSciences AG and QureInvest AG.
Dr. Edward Stuart, Managing Partner
Dr Edward Stuart is a co-founder of HS LifeSciences AG. He started his industrial career as COO of DeveloGen AG before co-founding and becoming the Managing Director and CBO of U3 Pharma AG. Subsequently, Dr. Stuart became the founding CEO of Neurimmune Therapeutics AG. He also acted as the founding CEO of CT Atlantic AG (Zurich, Switzerland), an oncology-focused spin-off from the University of Zurich and the Ludwig Institute for Cancer Research and the first portfolio company of HS LifeSciences.
He studied pharmacology in University College Dublin, Ireland, where he was awarded his PhD and was a post-doctoral scientist at the Max Planck Institute in Gottingen followed by his appointment as a Lecturer in Medical Genetics in Imperial College London, UK. Dr. Stuart also holds an MBA from The Business School of Imperial College London, UK.
Mr. Justin Duckworth, Managing Partner
Justin Duckworth is a member of the Board of HS LifeSciences AG. Mr Duckworth has spent the last 10 years working for venture capital funds within life sciences, most recently as a Partner at Nomura Phase4 Ventures. During this period Mr. Duckworth invested as a Lead or Co-Lead investor in 7 new company financings in addition to numerous follow-on financings. Prior to Nomura, Mr Duckworth worked as an Investment Advisor at HBM Partners in Zurich and a Vice President in the Private Equity group of Dresdner Kleinwort Wasserstein in London.
Prior to 2000, Mr Duckworth worked in a number of roles within Arthur Andersen in London and gained his ACA qualifications. He is a member of the ICAEW and has an MA (Oxon) in Biochemistry from the University of Oxford.
Dr. Christian Wenger
Dr Christian Wenger, lawyer, is a partner at Wenger & Vieli, a Zurich-based law firm, and a specialist for private equity, venture capital and M&A transactions. In addition, he is member of the Board of SECA (Swiss Private Equity & Corporate Finance Association) and Chairman of CT Invest, the leading Swiss Venture Platform.
Dr. Wenger serves on several Supervisory Boards, e.g. AIG Private Bank, Klinik Lindberg AG, and Looser Holding AG an Chairman of the Board of Chemolio Management AG.
He holds a Master of Law from Duke University of Law, North Carolina and earned his doctorate at the University of Zurich.
